HF2275 modifies Minnesota’s insulin manufacturer registration fee law. Under current law, insulin manufacturers are assessed an annual $100,000 registration fee. This bill keeps that fee in place but changes the exemption standard so that a manufacturer may request relief from the fee if it can show that its insulin sales in Minnesota account for less than 5% of the total gross wholesale acquisition cost of all prescription insulin sold or delivered in or into Minnesota during the previous calendar year.
The bill also directs the board to notify manufacturers of the fee requirement each November 1 beginning in 2024 and requires the commissioner of health to provide technical assistance to the board using available data sources, including data collected under section 62U.04. In practical terms, the bill refines how the fee is administered and how exemptions are determined, while preserving the overall fee structure for insulin manufacturers.
Impact
HF2275 amends Minnesota Statutes 2024, section 151.741, subdivision 2, affecting the state’s insulin manufacturer registration fee program. It changes the exemption criteria for manufacturers seeking relief from the annual fee and reinforces administrative duties for the board and the commissioner of health. The bill primarily affects insulin manufacturers operating in or selling into Minnesota, and it may reduce fee obligations for smaller-market participants that meet the new threshold.
Sentiment
The available record suggests a generally policy-focused and noncontroversial treatment of the bill, with no recorded committee debate or votes in the provided materials. The bill’s subject matter—insulin pricing and manufacturer oversight—indicates a consumer-protection and health-affordability rationale, but the absence of transcripts or vote data means there is no documented opposition or support to characterize beyond the bill’s introduction and referral.
Contention
No specific points of contention are documented in the provided materials. Potential areas of debate, based on the text, could include whether the 5% exemption threshold is too broad or too narrow, how the wholesale acquisition cost metric should be applied, and whether the fee and exemption structure appropriately balances regulatory oversight with the burden on manufacturers. However, no named stakeholders or opposing positions are recorded in the available context.